Glucotrack Combines with Lōkahi Therapeutics

Glucotrack has completes its business combination with Lōkahi Therapeutics, creating a platform to identify, acquire, and advance differentiated healthcare assets.

Lōkahi will become the combined company’s operating and controlling business. Glucotrack’s continuous blood glucose monitoring (CBGM) business will become a wholly owned subsidiary with operations, assets, and capital structure separately maintained.

The merged organization combines Lōkahi’s late-stage clinical development program and ai²-driven asset sourcing/advancement platform with Glucotrack’s tech infrastructure. Part of the proceeds from this transaction will be used to support continued development and operation of Glucotrack’s legacy CBGM in a dedicated subsidiary structure.

Lōkahi chief executive Erik Emerson was appointed CEO of the combined company.

“This transaction establishes a capital-efficient, publicly listed platform designed to systematically identify, acquire, and advance differentiated healthcare assets,” Emerson said. “By combining public market access with Lōkahi Therapeutics’ ai² platform and disciplined operating model, we are positioned to expand our pipeline, strengthen our capital structure, and pursue a broader set of strategic opportunities.”

Paul Goode, CEO of Glucotrack, will move to chief technical officer for the combined company.

“This combination enables the continued advancement of Glucotrack’s core technology within a focused operating structure while participating in a broader platform designed for scalable growth,” Goode told the press. “We believe this integrated approach supports disciplined execution across both operating priorities.”